Bing Yao, ArriVent Biopharma CEO

Scoop: Bing Yao’s Ar­riVent lin­ing up $145M raise, af­ter $150M de­but in 2021

Bing Yao took his pre­vi­ous biotech through three key mile­stones: IPO, drug ap­proval and an M&A ex­it. Now, he’s lin­ing up an­oth­er round of fi­nanc­ing for his bet on bring­ing Chi­nese R&D to the States.

Ar­riVent Bio­phar­ma de­buted with a $150 mil­lion round in June 2021. New pa­per­work filed with the SEC last week out­lines a sec­ond round of fi­nanc­ing is in the works for up to $145 mil­lion. The fil­ing doc­u­ments 17 in­vestors so far lin­ing up $110 mil­lion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.